Gilles Della Corte, M.D., joined Relief in September 2020 as Chief Medical Officer. At Relief, Gilles is responsible for the clinical development of RLF-100™ in Europe and coordinating closely with NeuroRx, which is responsible for clinical trials in the U.S., as well as interactions with and submissions to regulatory authorities. He brings over 40 years of professional experience, including 30 years in the biopharmaceutical industry. Gilles held several senior clinical research positions at Merck Serono (previously Serono), where he was responsible for the development from proof of concept to life cycle management of projects in several disease areas, including cardiology, rheumatology, oncology and endocrinology. Earlier in his career, he also held positions of increasing responsibility at several clinical research organizations (CROs), pharmaceutical and start-up companies, including Rhone-Poulenc-Rorer, Servier, Solvay Pharma, as well as Phoenix Life Sciences, Larime, Omnicare Clinical Research, Therapharm, and Anergis. In 2016, Dr. Della Corte founded Dellmed Consulting, providing strategic advice and hands-on support for clinical development in various therapeutic areas, such as dermatology, oncology, allergy, and for CRO selection for companies ranging from biotech start-ups to well established pharmaceutical companies.
Gilles holds an M.D. from Paris-Sud University (Paris XI) and is a Board-certified cardiologist with ten years of hospital practice.